{"ticker": {"uuid": "08f21f1a-3a3b-4928-aeda-4b66067c72ea", "symbol": "ARTL", "name": "Artelo Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOWEVHS2V1Z0VRMFltMHdhY3dsTkdyMFRBM1ZnY1R5ZGdORlIweWRERzA3TC1hbFFabFRkc2d3RGkxZG8zdTBDWF9rWTRnZjNyVVFHODJJZW9QN1pUOFFrWVpkZklGaVpfcnItOXNwMUJjOWpGQ1pfQmpvVWtyNUlrbTFQeldHZzJuOGFyRHd2VEFzdm9MS0RPWjJ6Yzkyek4tSEp6WHNDbUJIelpyYXFfbkNXU1dCZHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:35:19+00:00", "published_display": "21 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (NASDAQ: ARTL) awards 136-share option to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPRXVpOHJsSzh5Q3lBZXpDSVl6enFmWUFNTWNNckdLRFFqMVJkeTlNY2JRLW12bzlUdWNUenkzbHh6ZW5MYjFVdG41Rmx3U3JVVDE3Q1BKZ1FCSFlpWC1wYUVPTTVfVG04LTZRZ1pVaEVkMXJHVGNoTUlQM1lOM3c5cTJja3BIT1RDVU5icHg1ZkpkNzBEem1ZdU9MVWRabkx4QWo0ajlPd19yN2pSeXh6anJPX0pzemc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:35:18+00:00", "published_display": "21 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) grants small stock option award to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPMzF6X0ppRWlGYV92VVlhNGFmR1dORWk3ZzhvdG56M2E0SkNVQ3k1QV9NZmRIYVdPeXpsYW1YQWFPNVo0S3NXM3hXSjk2WnVqN0J4ZnlaejZNbjVqX05iSk16QnplWlo5REI5ZG5lNFJrRlBVWlhhSkdMcWVTUkVPdHVvallSSDZJRzJ2R3pxX3djbW1sQzVYaURJYzJHby1TdGp3b1hJUmc1OHVkNjJGUVNGR3FVOFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:32:07+00:00", "published_display": "21 Jul 2026 22:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences grants options to director | ARTL Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNckJOeUVlVksxdld1d0g3a3ZRTXFydWtzcG0xd3BiZk82UGVRODNFSW1MNHVrRmJGLWVxUWJnVHRtSF9RRUdUU1Yyd2dBbGJLRzJmcDZuQmZCS3JDLTVKVDBUNUsyamRDLU1ZRF90UWZDaDJIQjVDQlZTR0VoOUswaTBoU3FYV1Zfbm1KZjVkMkVNX000aDl0bVN1T0lxOUJhcmhvUXFTRXFabnRRdVladGdYTWEtcUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:27:44+00:00", "published_display": "21 Jul 2026 22:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) Proxy filing Summary", "summary": "Artelo Biosciences' annual meeting on July 17, 2026, will address three key proposals: electing Class III directors, increasing authorized common stock from 166,666,667 to 500,000,000 shares, and approving the issuance of more than 20% of outstanding common stock for Nasdaq compl", "url": "https://quartr.com/events/artelo-biosciences-inc-artl-proxy-filing_FkOrfuk2", "source_name": "Quartr", "published_at": "2026-07-19T03:10:55", "published_display": "19 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) AGM 2026 Summary", "summary": "Artelo Biosciences (ARTL) held its 2026 Annual General Meeting, where shareholders considered several key proposals. These included the re-election of three Class III directors, an amendment to increase the authorized common stock from 166,666,667 to 500 million, and approval for", "url": "https://quartr.com/events/artelo-biosciences-inc-artl-agm-2026_FkOrfDsB", "source_name": "Quartr", "published_at": "2026-07-17T20:11:58", "published_display": "17 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (NASDAQ: ARTL) details 2026 director and shareholder vote tallies", "summary": "Artelo Biosciences, Inc. (NASDAQ: ARTL) reported the results of its Annual Meeting of Stockholders held on July 17, 2026. Stockholders voted on the re-election of three Class III directors and approved two other proposals, including an increase in authorized common stock and a sh", "url": "https://www.stocktitan.net/sec-filings/ARTL/8-k-artelo-biosciences-inc-reports-material-event-6cdf63ee62ea.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:11:58", "published_display": "17 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTL: All proposals, including director elections and share increases, were approved", "summary": "Artelo Biosciences, Inc. (ARTL) shareholders approved all proposals during their 2026 AGM, including director elections, an increase in authorized shares, and a major equity issuance. No shareholder questions were raised during the Q&A session. This information is based on the co", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3853404:0-artl-all-proposals-including-director-elections-and-share-increases-were-approved/", "source_name": "TradingView", "published_at": "2026-07-17T16:11:58", "published_display": "17 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxPbDdPY1M3U0hDeFFJYkxpeGl6aWtvSGRvZDlocTRyR3J0YjhmcjVQXzl0aDk0OUFQRUVrVFZGLTNFRm91LWlNdGZSVW9kQnJFUEF0MWpiUG15dHhtaFQzbkJyODV3VGk0MjNLSTllSkNDM0ZzbU9Gd1pOLUJFaVpITEkxRkhtUURSSWhqQzlDVXNpMTd0SDlENERUSHdJYlpWUnJyT20xTm1tQmVTWDNocTlNUTVCS1VFSWdLVXpjQlVGUzgtX053V2tkcUwtN0lhWFU5ZnFnVFVfaTFiem1ibWlhRmhhQmUzS2lqXzd1NjBneHJRcWFWNGxQNkd0WWJUYWFmdWN6RlR3TUQyU0ViamFzZFNxdnZwQWctUC15OG9UQQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-17T11:47:49+00:00", "published_display": "17 Jul 2026 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo presents preclinical data on osteoarthritis pain drug", "summary": "Artelo Biosciences announced preclinical study results for ART26.12, its osteoarthritis pain drug, showing it reduced pain behaviors in studies and had comparable efficacy to naproxen with fewer side effects. The company plans to start a clinical study in Q4 to evaluate its safet", "url": "https://m.uk.investing.com/news/stock-market-news/artelo-presents-preclinical-data-on-osteoarthritis-pain-drug-93CH-4774123?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-17T10:11:58", "published_display": "17 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) Advances ART26.12 for Osteoarthritis P", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNUmMwaEZma05TcjN4djJYblFlR2YzUlg2SVByM3puYW1UbmRZWENXWG5oS2ZaNTRGT0FGZ3NyUUU3dEdiZHdGQ3BidEM3anFWaV9GWmZOTmZ2ZUt6cFRFOFpSYl96dk01SVIxT2RjbWU4WGEwdk5LTXFKb0Jfb2JaZXhqX0ZwbWY3MjRhRzdqWUZqOWJLbklOYkJtNWtTeXg0WlFFQ1JEYkVheEEzMl80UThzXy1rSUZ2Z3B2VEt0cw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T19:20:03+00:00", "published_display": "16 Jul 2026 19:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions", "summary": "Artelo Biosciences announced positive nonclinical study results for ART26.12, its FABP5 inhibitor, showing its potential as a first-in-class treatment for osteoarthritis pain. The drug demonstrated efficacy comparable to naproxen in reducing pain, while significantly minimizing g", "url": "https://www.marketscreener.com/news/artelo-biosciences-inc-announces-results-from-nonclinical-osteoarthritis-study-supporting-art26-12-ce7f5ed3dd89f52d", "source_name": "www.marketscreener.com", "published_at": "2026-07-16T18:09:40", "published_display": "16 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions", "summary": "Artelo Biosciences announced positive results from a nonclinical osteoarthritis study for its proprietary compound ART26.12, a selective FABP5 inhibitor. The study showed ART26.12 significantly reduced OA-associated pain behaviors comparable to naproxen, but with significantly le", "url": "https://finance.yahoo.com/healthcare/articles/artelo-biosciences-announces-results-nonclinical-124800698.html", "source_name": "Market source", "published_at": "2026-07-16T14:40:07", "published_display": "16 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Says New Data Shows ART26.12 Reduces Osteoarthritis Pain", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/artelo-biosciences-says-data-shows-133820580.html", "source_name": "MT Newswires", "published_at": "2026-07-16T13:38:20+00:00", "published_display": "16 Jul 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo's ART26.12 Matched Naproxen for Pain With Less Stomach Damage", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQUDlUSUZCTmpCSW1RV0ZNczV6ZnVyMk9TaUZzR3haV29RdXJKOXZRSGNSaXA3N0JtQmpKUnk0Zy1QaENvTU5uYmdCM1pLR00wWE5PQ0hncFVUbjJzblRiQ1ZxRk9BMWx1T19EVUIwMXhuNUlyY3hOamFUUjI0RGRpT1dScVdsOW4zSjNhaWFOQk45S1Q0VE1udGVOUUdhRUU1SWM5T24wNndTZWRuaEpR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:48:00+00:00", "published_display": "16 Jul 2026 12:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026", "summary": "Artelo Biosciences is reminding its shareholders to vote their shares before its Annual Meeting on July 17, 2026. The company emphasizes that submitting a proxy is crucial for establishing the necessary quorum, regardless of how shareholders choose to vote. This participation ens", "url": "https://www.manilatimes.net/2026/07/14/tmt-newswire/globenewswire/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-advance-of-annual-meeting-on-july-17-2026/2384163/amp", "source_name": "The Manila Times", "published_at": "2026-07-15T02:09:40", "published_display": "15 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Every Artelo proxy helps reach quorum for July 17 meeting", "summary": "Artelo Biosciences is reminding shareholders to vote their shares in advance of its virtual Annual Meeting on July 17, 2026, to ensure a quorum is met. The company emphasizes that every proxy submitted, regardless of the vote (FOR, AGAINST, or ABSTAIN), contributes to establishin", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-ah3aty12p0kz.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:46:42", "published_display": "14 Jul 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo reports ART27.13 pain study results", "summary": "Artelo Biosciences announced nonclinical results showing its drug candidate ART27.13 reduced neuropathic pain behaviors in an animal model. The cannabinoid receptor agonist decreased mechanical allodynia and thermal hyperalgesia after repeated dosing. These findings support furth", "url": "https://grafa.com/en/news/united-states/artelo-art27-13-neuropathic-pain-study-results", "source_name": "grafa.com", "published_at": "2026-07-13T18:10:49", "published_display": "13 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo reports positive neuropathic pain study results for ART27.13", "summary": "Artelo Biosciences announced positive nonclinical study results for its drug candidate ART27.13, showing it reduced neuropathic pain in a paclitaxel-induced peripheral neuropathy model. The company, facing financial challenges with a 98% stock drop over the past year, is also adv", "url": "https://m.uk.investing.com/news/stock-market-news/artelo-reports-positive-neuropathic-pain-study-results-for-art2713-93CH-4767967?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T18:10:49", "published_display": "13 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Says ART27.13 Decreases Neuropathic Pain-linked Behaviors in Animals Treated With Paclitaxel", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/artelo-says-art27-13-decreases-133139466.html", "source_name": "MT Newswires", "published_at": "2026-07-13T13:31:39+00:00", "published_display": "13 Jul 2026 13:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer Patients", "summary": "Artelo Biosciences announced promising nonclinical and interim clinical data for ART27.13, their proprietary cannabinoid receptor agonist, suggesting its potential to treat neuropathic pain and cancer-related anorexia cachexia syndrome (CACS) in cancer patients. Nonclinical studi", "url": "https://www.quiverquant.com/news/Artelo+Biosciences+Announces+ART27.13+Data+Suggest+Potential+Benefit+for+Neuropathic+Pain+in+Cancer+Patients", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T13:10:49", "published_display": "13 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer pain study: ART27.13 eases nerve pain signs in paclitaxel-treated animals", "summary": "Artelo Biosciences announced positive nonclinical data for its drug ART27.13, showing it reduced neuropathic pain in animals treated with paclitaxel. These findings suggest a broader application for ART27.13 in cancer supportive care beyond its current Phase 2 development for can", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-announces-positive-results-with-art27-13-in-a-ova49n2hjnvn.html", "source_name": "Stock Titan", "published_at": "2026-07-13T13:01:51", "published_display": "13 Jul 2026 13:01", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy", "summary": "Artelo Biosciences announced positive results for ART27.13 in a nonclinical model of paclitaxel-induced peripheral neuropathy, a common and debilitating side effect of chemotherapy. The study showed that ART27.13 reduced neuropathic pain behaviors in animals, suggesting its poten", "url": "https://finance.yahoo.com/healthcare/articles/artelo-biosciences-announces-positive-results-130200272.html", "source_name": "Market source", "published_at": "2026-07-13T09:02:00", "published_display": "13 Jul 2026 09:02", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ARTL - Artelo Biosciences Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Artelo Biosciences Inc (ARTL). It includes key metrics such as market capitalization, income, sales, various financial ratios, insider ownership, institutional ownership, and stock performance data.", "url": "https://finviz.com/stock?t=ARTL&p=w&ty=lf&b=1&page=12", "source_name": "Finviz", "published_at": "2026-07-02T12:11:17", "published_display": "02 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces New Data Support", "summary": "This article announces that Artelo Biosciences has revealed new data supporting its research. The company's findings are expected to have significant implications for its ongoing projects and future developments. Further details about the data and its impact may be available from", "url": "https://www.moomoo.com/news/flash/22730451/artelo-biosciences-announces-new-data-supporting-art26-12-as-a", "source_name": "Moomoo", "published_at": "2026-07-02T10:40:45", "published_display": "02 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury", "summary": "Artelo Biosciences announced new preclinical data supporting ART26.12 as a potential first-in-class therapy for chronic neuropathic pain associated with spinal cord injury. The study, conducted at Stony Brook University, showed that ART26.12, a selective FABP5 inhibitor, alleviat", "url": "https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/artelo-biosciences-announces-new-data-supporting-art2612-as-a-potential-first-in-class-therapy-for-chronic-pain-associated-with-spinal-cord-injury/2376730", "source_name": "The Manila Times", "published_at": "2026-07-01T22:39:53", "published_display": "01 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo's ART26.12 eased spinal cord injury pain in mice", "summary": "Artelo Biosciences announced new preclinical data supporting ART26.12 as a potential \"first-in-class\" therapy for chronic pain associated with spinal cord injury. Studies in mice demonstrated that ART26.12, a selective FABP5 inhibitor, reduced mechanical hypersensitivity, decreas", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-announces-new-data-supporting-art26-12-as-a-a65cynz9unhk.html", "source_name": "Stock Titan", "published_at": "2026-07-01T13:09:06", "published_display": "01 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo presents research on FABP5 inhibitor ART26.12", "summary": "Artelo Biosciences presented research findings on its lead drug candidate ART26.12, a FABP5 inhibitor, at an international symposium. The multi-omics analyses identified linoleic acid as a central link in FABP5 inhibition, aligning with previous cancer research. Despite a signifi", "url": "https://m.uk.investing.com/news/stock-market-news/artelo-presents-research-on-fabp5-inhibitor-art2612-93CH-4750728?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-01T08:40:08", "published_display": "01 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026", "summary": "Artelo Biosciences announced multi-omics analysis results at the ICRS 2026 Annual Symposium, highlighting linoleic acid as a critical lipid modulated by their lead FABP5 inhibitor, ART26.12. This finding suggests a common mechanistic link for FABP5 inhibition across various disea", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/artelo-biosciences-presents-evidence-for-a-common-lipid-signaling-link-across-multiple-potential-indications-for-its-fabp5-inhibitor-platform-at-icrs-2026/2375833/amp", "source_name": "The Manila Times", "published_at": "2026-06-30T21:09:06", "published_display": "30 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo says its FABP5 inhibitor hits a key lipid pathway across disease models", "summary": "Artelo Biosciences announced new multi-omics data for its selective FABP5 inhibitor, ART26.12, showing consistent modulation of the pro-inflammatory lipid linoleic acid and related lipid-signaling pathways across various disease models. This suggests a potential mechanistic link ", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-presents-evidence-for-a-common-lipid-signaling-kg1z5lyxzgae.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:39:30", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research", "summary": "Artelo Biosciences announced positive Phase 1 clinical trial results for ART26.12, its selective FABP5 inhibitor, showing a favorable safety profile and predictable pharmacokinetics. The study highlighted ART26.12's potential as a non-opioid analgesic for chemotherapy-induced per", "url": "https://www.quiverquant.com/news/Artelo+Biosciences+Reports+Positive+First-in-Human+ART26.12+Safety+and+Pharmacokinetic+Results%2C+Advances+AI-Enabled+Biomarker+Research", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T21:09:06", "published_display": "29 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo\u2019s first-in-human FABP5 inhibitor shows tolerability, biomarker signals", "summary": "Artelo Biosciences reported positive Phase 1 clinical data for its selective FABP5 inhibitor, ART26.12, at ICRS 2026. The study found ART26.12 to be well-tolerated with predictable pharmacokinetics, and AI-driven analysis identified treatment-related changes in various biological", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-presents-clinical-and-biomarker-data-supportive-pjjo1myuhfej.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:10:13", "published_display": "29 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026", "summary": "Artelo Biosciences announced the presentation of clinical and biomarker data for ART26.12, its selective FABP5 inhibitor, at the ICRS 2026 Annual Symposium. The presentations highlighted favorable safety and pharmacokinetic profiles from a Phase 1 study and identified potential b", "url": "https://sg.finance.yahoo.com/news/artelo-biosciences-presents-clinical-biomarker-124500525.html", "source_name": "Market source", "published_at": "2026-06-29T13:10:13", "published_display": "29 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Inc Actuals & Estimates (NASDAQ:ARTL)", "summary": "This article provides details on Artelo Biosciences, Inc. (NASDAQ: ARTL), including its current stock price, historical performance, market capitalization, and upcoming earnings report. As of June 26, 2026, ARTL's stock price is $1.12, having decreased significantly year-over-yea", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:21", "published_display": "26 Jun 2026 19:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) asks shareholders to approve >20% issuance to Square Gate", "summary": "Artelo Biosciences is seeking shareholder approval for Proposal 3, which would allow the company to issue more than 20% of its common stock under an existing Equity Purchase Agreement (EPA) with Square Gate Capital Master Fund, LLC \u2013 Series 5. This approval is necessary to comply", "url": "https://www.stocktitan.net/sec-filings/ARTL/prer14a-artelo-biosciences-inc-preliminary-revised-proxy-statement-0ac81b42277c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:14", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides an analysis of Artelo Biosciences Inc (ARTL), detailing its stock performance and market capitalization. It highlights that critical revenue breakdown data, including information by business segment and region, has not yet been disclosed by the company. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artl/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:15:28", "published_display": "18 Jun 2026 09:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artelo-biosciences-presents-art26-12-113800180.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:38:00+00:00", "published_display": "10 Jun 2026 11:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTL Stock In Focus As Artelo Biosciences Taps AI For Drug Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOVTNiNFZSc1Z2ZGRsakhSeUVva1lzczJyajJWMEpIMlNvdTBsTGI0MVJ1WTRURWY1MENHakVQRU51Q08xcVFHSFdRR2tFLXVybGRPVmhObW10WC1qMU9xWWd5STh5VDdFeDcwM3hKN3JLclRCdGxUaHVGZjhhMF8zVg?oc=5", "source_name": "StocksToTrade", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Artelo keeps Nasdaq listing after fixing equity, meeting gaps", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQckFoNERSUmhWLU01aUFrNGZWdjBxSVhQTE95LUJJemxFUXJXcE1GZFMxQ09tcjBVZjBXM0x3U3BNU2NZM2xUX3JDRmJ1cnhNNm15UXY5NWduY3Z6SWFXTzFlZU1zYjQ3cEFFSWU2QzJDWlBId1p6TG9XUFNqMnRCN3hGQjdQcnZzRXhKWmxpM08zejdNcjB4YVVYZ3BvV01KVHh3T05uVk96UWM3RTlmTEx3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] ARTELO BIOSCIENCES, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNY0hrLW8yOHQzQ1htTDYxT012VlczamFtcjdnZDBUX1VTR0xUMFh6REViSlFINzBxWU1lTW5tZU56ZnhlSklua1JMSlF3ZVgwZkgxRmhNdm9DWHZPQmxqWEJ6YUpBMGN3clpUbVh5NDhYSjdSREVmN0N6cU1Dc1B3Q2hsQ2VaUWFaakNJQ1RvZWc3TzFBYlY5b3lyd1dVTFAzZ2VkZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo raises $11M now; warrant exercise would add $20.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMHN5VEQ0dW1ydENmVjlNcDUtZVpvTWtWalNlYXpmTExROEV4bzVmX2dLbHVXdzRsUWlKd2toMTFscFBkQWZsY0JGcmdBYTN5ejN6TjIxQmRaOHhOYzhXaVFsS0laRkVETGlhOFFoR1J6bFJ5X0JOTVl5X0JBVWQ1SGxFOWhuV1J0Zmk0Z3R0SkRiRnR6M1dOekpTVmdlbFdLRTBQbHBBbEdRdElURzRsNElqZzhmZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences, Inc. Completes $11 Million Private Placement of Common Stock and Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNb2lOSGpSeDVyeEU2RXJCcHZxenM1YS1kS2RFSTBGeGx4aU9OUzhtalp4VzVIR2xJWGhiUld3eHAwUk03WnlET2FyZnJnS25tNzBXY1liZ005TlhvQzI5eGd6VW8xbkItRjVnc2hOS3drakFuWkp0eC01YnFZeGVYd3dHU19fVmh3bGI2VmJ4SXVtZl9FZFY5dElvdERDbktkR254Szc2Ti1mSEplcUhoVjZmSzMzZ1F1OTRZdW11c2xRUFlpYUFjVXJ3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxOQ01pOUQ0SzU1SWFLWjZDTHZMNFF0V3BMcEdiQXNmLVduNjRrSG1RM3gwUEpJcGhnbHpyQVAwVTVQcUJ6X3hsLUlhNjFUMnJwNW5GMVgwOEFfekNUZ082bEI1bzBONEFVVHUzSlRGRC1aU3ZCd0NsZ2VwQnFUTEJFQnEwMXkza0otSE1EbXpDM0FEYUVhZ1hFUkg0bFdhZEhfVlF5MElZZVVTcnozRnotZUlmZmtZejJUTXFZa3J5a2dEZWxZcXAyMTJ5OEwtQm5CbHhXTWl6MkxqaU1fVEQ0V2d5VHBpbHFfZ0pKdzRROVpqS24tR182Z2IzTlFMNXdoVjM1VHFROEUxLWVTN3pz?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Artelo Biosciences, Inc. Announces Private Placement of Common Stock and Warrants, Expected Proceeds of $11 Million | ARTL Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPZUZKSTAyam1VbkFROUVXTTBRU0U0dVdncmxPdHNiVzJYWDRhZVB2aUVtNEdGSUg2NTZ6OC1VWUdiT1BzVWcwbE5OTU9TSWlFR2JVcWpETm4yRDNXNjZNTzg4YmIzUWlLd0k2d1Vhck42N3ZFNVhzX1FPVXUtZFhuZm5WV1BqQ3pVQm51LTE2UkxCWkV6ZFJCMjA4bU5tZGxUU1NsaVJQRElTWU5ZVDdGcUx2clczdXAzWUhCRmhSRWxjeVZNUlk3bEE1VWF0eVF3eDlpS0tfbTdnNm1UMEV0dm90YkUxWl9RZ0E?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPRlUwQm9KNHY4U3VxeUZpZ0YwZHB2ZVEtMWN4WnE1S0JKRVI4TDd5UTJLbEVYdFhKUVhtUVNCM3kwN2NEOXJET1lUY3FpeDdJU0xjSzJqTkViY1p4cTYwMU1ldnNRUWZnbFRQSm5UekNqRU1FWVpXb203V0prMzFsOXRzUmZ2ckNtaDhqUnV6NnBKbDIxeHJZT2hRSXNoTmgydkJqb2VHMEs1Y2dvN3NnNk5BMjlUOWgyMWJZTjJkekdKUFFxZ05VWnRMcHdSczRRYTBqcWFsa1liSUtmOHdJREpvVW1mb2FnTk5EZzRPRkt5c3dUUG5zdlNpQ0ZHcVpL?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$11M Artelo stock sale targets debt repayment, working capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQdkxrejE1SDgxYUNkTFJWb1NzZnBOblhLZ3oxcjlLU0xfNlZ0Z3dHR1JjaWd4YzJYZ21PMldJRjNwck5GZmtMcGIycDdQMldVb0YydWxfem02RnpkWFl4b1ZRSFNnRE9jX0NNc1RKS2QyWTNKclNJdFpHLW1DSlZYNWZVT1l1YU5kTFc4blpzLUpXZDEwX0xDcy11dlhrQmkyS18tVVVrV0tybFRyQU5TYUpyUUV6M3VBTk52bUhR?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTELO BIOSCIENCES, INC. SEC Filing (Mar 27, 2026) | ARTL RW", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNVEZlSWw5U0JVTUtjMmp4UzVhYk5NWlhfMWk1cExzOXp4aU01SlF0YjcwY19sdkdsNEpaUHFMOFJmb2s2SHZWVjg4T21FVWlvZmRWbXpCQ1FsUmQzM3o4c3hmVzdLdDZDNjJVYi1tN0JkUk9jSmV0ckxsUWVXMDRvUFBhd0Y1RGpmTE9pa3U1MFRZdy1VaTlQaThPbnF1N0k?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo takes its lead drug into glaucoma without paying for the trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdGxyejNaYTRjSE93YnI1Z25uYmdTalQ4clhkM1ZBQmdYVkp2QUdrOW5uMUdLZTlkWUhTXzNWYzBvQmI4QkhGNFpDZUJXcEZVQ3dhdmdtRWRva181SHFHNFVxVUNHMEJBXy1kNGN3bTljeC1nTExNdndVTlpuVEVDMTZPb2RLVFBYekFYUWZhVXZwZkd6ckVjb01mQjBaalZoVDBodHlTVGJmS19WREktMTRwY2kyeE1tY0tTYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo shrinks share count to 708K in 3-for-1 reverse split", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQUU9UYzhNM3lJSV9wQVNBWWNRaExHRHhDdlBGX3RWRlg0bjdaSVllVHR6c0V4NjZYRTRHM3RhYUpNY3BCRVMxYm53RDN6N09raXFsdHdUbzZ4TmtJUGZDR01QZFUxN2RYODRQb1FPNXVrMEVyNGpfc0hFQS1LampWSEN1ME04T3NSRXB3UHhXMWdEM3JJa0taY0VfOWtBQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5wX25RY0toY3FBVmNuWUtxd1paUnhPY19VU2lsYVZvcGcxUnBaZFhkVU4zYXU5R2dXczM4aG5Zd0dodldqRW1lanFVTWZVYWc5NHpB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:14:23+00:00", "published_display": "25 Apr 2025 02:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOWEVHS2V1Z0VRMFltMHdhY3dsTkdyMFRBM1ZnY1R5ZGdORlIweWRERzA3TC1hbFFabFRkc2d3RGkxZG8zdTBDWF9rWTRnZjNyVVFHODJJZW9QN1pUOFFrWVpkZklGaVpfcnItOXNwMUJjOWpGQ1pfQmpvVWtyNUlrbTFQeldHZzJuOGFyRHd2VEFzdm9MS0RPWjJ6Yzkyek4tSEp6WHNDbUJIelpyYXFfbkNXU1dCZHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:35:19+00:00", "published_display": "21 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (NASDAQ: ARTL) awards 136-share option to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPRXVpOHJsSzh5Q3lBZXpDSVl6enFmWUFNTWNNckdLRFFqMVJkeTlNY2JRLW12bzlUdWNUenkzbHh6ZW5MYjFVdG41Rmx3U3JVVDE3Q1BKZ1FCSFlpWC1wYUVPTTVfVG04LTZRZ1pVaEVkMXJHVGNoTUlQM1lOM3c5cTJja3BIT1RDVU5icHg1ZkpkNzBEem1ZdU9MVWRabkx4QWo0ajlPd19yN2pSeXh6anJPX0pzemc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:35:18+00:00", "published_display": "21 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) grants small stock option award to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPMzF6X0ppRWlGYV92VVlhNGFmR1dORWk3ZzhvdG56M2E0SkNVQ3k1QV9NZmRIYVdPeXpsYW1YQWFPNVo0S3NXM3hXSjk2WnVqN0J4ZnlaejZNbjVqX05iSk16QnplWlo5REI5ZG5lNFJrRlBVWlhhSkdMcWVTUkVPdHVvallSSDZJRzJ2R3pxX3djbW1sQzVYaURJYzJHby1TdGp3b1hJUmc1OHVkNjJGUVNGR3FVOFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:32:07+00:00", "published_display": "21 Jul 2026 22:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences grants options to director | ARTL Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNckJOeUVlVksxdld1d0g3a3ZRTXFydWtzcG0xd3BiZk82UGVRODNFSW1MNHVrRmJGLWVxUWJnVHRtSF9RRUdUU1Yyd2dBbGJLRzJmcDZuQmZCS3JDLTVKVDBUNUsyamRDLU1ZRF90UWZDaDJIQjVDQlZTR0VoOUswaTBoU3FYV1Zfbm1KZjVkMkVNX000aDl0bVN1T0lxOUJhcmhvUXFTRXFabnRRdVladGdYTWEtcUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:27:44+00:00", "published_display": "21 Jul 2026 22:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) Proxy filing Summary", "summary": "Artelo Biosciences' annual meeting on July 17, 2026, will address three key proposals: electing Class III directors, increasing authorized common stock from 166,666,667 to 500,000,000 shares, and approving the issuance of more than 20% of outstanding common stock for Nasdaq compl", "url": "https://quartr.com/events/artelo-biosciences-inc-artl-proxy-filing_FkOrfuk2", "source_name": "Quartr", "published_at": "2026-07-19T03:10:55", "published_display": "19 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) AGM 2026 Summary", "summary": "Artelo Biosciences (ARTL) held its 2026 Annual General Meeting, where shareholders considered several key proposals. These included the re-election of three Class III directors, an amendment to increase the authorized common stock from 166,666,667 to 500 million, and approval for", "url": "https://quartr.com/events/artelo-biosciences-inc-artl-agm-2026_FkOrfDsB", "source_name": "Quartr", "published_at": "2026-07-17T20:11:58", "published_display": "17 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (NASDAQ: ARTL) details 2026 director and shareholder vote tallies", "summary": "Artelo Biosciences, Inc. (NASDAQ: ARTL) reported the results of its Annual Meeting of Stockholders held on July 17, 2026. Stockholders voted on the re-election of three Class III directors and approved two other proposals, including an increase in authorized common stock and a sh", "url": "https://www.stocktitan.net/sec-filings/ARTL/8-k-artelo-biosciences-inc-reports-material-event-6cdf63ee62ea.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:11:58", "published_display": "17 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTL: All proposals, including director elections and share increases, were approved", "summary": "Artelo Biosciences, Inc. (ARTL) shareholders approved all proposals during their 2026 AGM, including director elections, an increase in authorized shares, and a major equity issuance. No shareholder questions were raised during the Q&A session. This information is based on the co", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3853404:0-artl-all-proposals-including-director-elections-and-share-increases-were-approved/", "source_name": "TradingView", "published_at": "2026-07-17T16:11:58", "published_display": "17 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxPbDdPY1M3U0hDeFFJYkxpeGl6aWtvSGRvZDlocTRyR3J0YjhmcjVQXzl0aDk0OUFQRUVrVFZGLTNFRm91LWlNdGZSVW9kQnJFUEF0MWpiUG15dHhtaFQzbkJyODV3VGk0MjNLSTllSkNDM0ZzbU9Gd1pOLUJFaVpITEkxRkhtUURSSWhqQzlDVXNpMTd0SDlENERUSHdJYlpWUnJyT20xTm1tQmVTWDNocTlNUTVCS1VFSWdLVXpjQlVGUzgtX053V2tkcUwtN0lhWFU5ZnFnVFVfaTFiem1ibWlhRmhhQmUzS2lqXzd1NjBneHJRcWFWNGxQNkd0WWJUYWFmdWN6RlR3TUQyU0ViamFzZFNxdnZwQWctUC15OG9UQQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-17T11:47:49+00:00", "published_display": "17 Jul 2026 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo presents preclinical data on osteoarthritis pain drug", "summary": "Artelo Biosciences announced preclinical study results for ART26.12, its osteoarthritis pain drug, showing it reduced pain behaviors in studies and had comparable efficacy to naproxen with fewer side effects. The company plans to start a clinical study in Q4 to evaluate its safet", "url": "https://m.uk.investing.com/news/stock-market-news/artelo-presents-preclinical-data-on-osteoarthritis-pain-drug-93CH-4774123?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-17T10:11:58", "published_display": "17 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) Advances ART26.12 for Osteoarthritis P", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNUmMwaEZma05TcjN4djJYblFlR2YzUlg2SVByM3puYW1UbmRZWENXWG5oS2ZaNTRGT0FGZ3NyUUU3dEdiZHdGQ3BidEM3anFWaV9GWmZOTmZ2ZUt6cFRFOFpSYl96dk01SVIxT2RjbWU4WGEwdk5LTXFKb0Jfb2JaZXhqX0ZwbWY3MjRhRzdqWUZqOWJLbklOYkJtNWtTeXg0WlFFQ1JEYkVheEEzMl80UThzXy1rSUZ2Z3B2VEt0cw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T19:20:03+00:00", "published_display": "16 Jul 2026 19:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions", "summary": "Artelo Biosciences announced positive nonclinical study results for ART26.12, its FABP5 inhibitor, showing its potential as a first-in-class treatment for osteoarthritis pain. The drug demonstrated efficacy comparable to naproxen in reducing pain, while significantly minimizing g", "url": "https://www.marketscreener.com/news/artelo-biosciences-inc-announces-results-from-nonclinical-osteoarthritis-study-supporting-art26-12-ce7f5ed3dd89f52d", "source_name": "www.marketscreener.com", "published_at": "2026-07-16T18:09:40", "published_display": "16 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions", "summary": "Artelo Biosciences announced positive results from a nonclinical osteoarthritis study for its proprietary compound ART26.12, a selective FABP5 inhibitor. The study showed ART26.12 significantly reduced OA-associated pain behaviors comparable to naproxen, but with significantly le", "url": "https://finance.yahoo.com/healthcare/articles/artelo-biosciences-announces-results-nonclinical-124800698.html", "source_name": "Market source", "published_at": "2026-07-16T14:40:07", "published_display": "16 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Says New Data Shows ART26.12 Reduces Osteoarthritis Pain", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/artelo-biosciences-says-data-shows-133820580.html", "source_name": "MT Newswires", "published_at": "2026-07-16T13:38:20+00:00", "published_display": "16 Jul 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo's ART26.12 Matched Naproxen for Pain With Less Stomach Damage", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQUDlUSUZCTmpCSW1RV0ZNczV6ZnVyMk9TaUZzR3haV29RdXJKOXZRSGNSaXA3N0JtQmpKUnk0Zy1QaENvTU5uYmdCM1pLR00wWE5PQ0hncFVUbjJzblRiQ1ZxRk9BMWx1T19EVUIwMXhuNUlyY3hOamFUUjI0RGRpT1dScVdsOW4zSjNhaWFOQk45S1Q0VE1udGVOUUdhRUU1SWM5T24wNndTZWRuaEpR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:48:00+00:00", "published_display": "16 Jul 2026 12:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026", "summary": "Artelo Biosciences is reminding its shareholders to vote their shares before its Annual Meeting on July 17, 2026. The company emphasizes that submitting a proxy is crucial for establishing the necessary quorum, regardless of how shareholders choose to vote. This participation ens", "url": "https://www.manilatimes.net/2026/07/14/tmt-newswire/globenewswire/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-advance-of-annual-meeting-on-july-17-2026/2384163/amp", "source_name": "The Manila Times", "published_at": "2026-07-15T02:09:40", "published_display": "15 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Every Artelo proxy helps reach quorum for July 17 meeting", "summary": "Artelo Biosciences is reminding shareholders to vote their shares in advance of its virtual Annual Meeting on July 17, 2026, to ensure a quorum is met. The company emphasizes that every proxy submitted, regardless of the vote (FOR, AGAINST, or ABSTAIN), contributes to establishin", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-ah3aty12p0kz.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:46:42", "published_display": "14 Jul 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo reports ART27.13 pain study results", "summary": "Artelo Biosciences announced nonclinical results showing its drug candidate ART27.13 reduced neuropathic pain behaviors in an animal model. The cannabinoid receptor agonist decreased mechanical allodynia and thermal hyperalgesia after repeated dosing. These findings support furth", "url": "https://grafa.com/en/news/united-states/artelo-art27-13-neuropathic-pain-study-results", "source_name": "grafa.com", "published_at": "2026-07-13T18:10:49", "published_display": "13 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo reports positive neuropathic pain study results for ART27.13", "summary": "Artelo Biosciences announced positive nonclinical study results for its drug candidate ART27.13, showing it reduced neuropathic pain in a paclitaxel-induced peripheral neuropathy model. The company, facing financial challenges with a 98% stock drop over the past year, is also adv", "url": "https://m.uk.investing.com/news/stock-market-news/artelo-reports-positive-neuropathic-pain-study-results-for-art2713-93CH-4767967?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T18:10:49", "published_display": "13 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Says ART27.13 Decreases Neuropathic Pain-linked Behaviors in Animals Treated With Paclitaxel", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/artelo-says-art27-13-decreases-133139466.html", "source_name": "MT Newswires", "published_at": "2026-07-13T13:31:39+00:00", "published_display": "13 Jul 2026 13:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer Patients", "summary": "Artelo Biosciences announced promising nonclinical and interim clinical data for ART27.13, their proprietary cannabinoid receptor agonist, suggesting its potential to treat neuropathic pain and cancer-related anorexia cachexia syndrome (CACS) in cancer patients. Nonclinical studi", "url": "https://www.quiverquant.com/news/Artelo+Biosciences+Announces+ART27.13+Data+Suggest+Potential+Benefit+for+Neuropathic+Pain+in+Cancer+Patients", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T13:10:49", "published_display": "13 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer pain study: ART27.13 eases nerve pain signs in paclitaxel-treated animals", "summary": "Artelo Biosciences announced positive nonclinical data for its drug ART27.13, showing it reduced neuropathic pain in animals treated with paclitaxel. These findings suggest a broader application for ART27.13 in cancer supportive care beyond its current Phase 2 development for can", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-announces-positive-results-with-art27-13-in-a-ova49n2hjnvn.html", "source_name": "Stock Titan", "published_at": "2026-07-13T13:01:51", "published_display": "13 Jul 2026 13:01", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy", "summary": "Artelo Biosciences announced positive results for ART27.13 in a nonclinical model of paclitaxel-induced peripheral neuropathy, a common and debilitating side effect of chemotherapy. The study showed that ART27.13 reduced neuropathic pain behaviors in animals, suggesting its poten", "url": "https://finance.yahoo.com/healthcare/articles/artelo-biosciences-announces-positive-results-130200272.html", "source_name": "Market source", "published_at": "2026-07-13T09:02:00", "published_display": "13 Jul 2026 09:02", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTL - Artelo Biosciences Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Artelo Biosciences Inc (ARTL). It includes key metrics such as market capitalization, income, sales, various financial ratios, insider ownership, institutional ownership, and stock performance data.", "url": "https://finviz.com/stock?t=ARTL&p=w&ty=lf&b=1&page=12", "source_name": "Finviz", "published_at": "2026-07-02T12:11:17", "published_display": "02 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces New Data Support", "summary": "This article announces that Artelo Biosciences has revealed new data supporting its research. The company's findings are expected to have significant implications for its ongoing projects and future developments. Further details about the data and its impact may be available from", "url": "https://www.moomoo.com/news/flash/22730451/artelo-biosciences-announces-new-data-supporting-art26-12-as-a", "source_name": "Moomoo", "published_at": "2026-07-02T10:40:45", "published_display": "02 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury", "summary": "Artelo Biosciences announced new preclinical data supporting ART26.12 as a potential first-in-class therapy for chronic neuropathic pain associated with spinal cord injury. The study, conducted at Stony Brook University, showed that ART26.12, a selective FABP5 inhibitor, alleviat", "url": "https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/artelo-biosciences-announces-new-data-supporting-art2612-as-a-potential-first-in-class-therapy-for-chronic-pain-associated-with-spinal-cord-injury/2376730", "source_name": "The Manila Times", "published_at": "2026-07-01T22:39:53", "published_display": "01 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo's ART26.12 eased spinal cord injury pain in mice", "summary": "Artelo Biosciences announced new preclinical data supporting ART26.12 as a potential \"first-in-class\" therapy for chronic pain associated with spinal cord injury. Studies in mice demonstrated that ART26.12, a selective FABP5 inhibitor, reduced mechanical hypersensitivity, decreas", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-announces-new-data-supporting-art26-12-as-a-a65cynz9unhk.html", "source_name": "Stock Titan", "published_at": "2026-07-01T13:09:06", "published_display": "01 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo presents research on FABP5 inhibitor ART26.12", "summary": "Artelo Biosciences presented research findings on its lead drug candidate ART26.12, a FABP5 inhibitor, at an international symposium. The multi-omics analyses identified linoleic acid as a central link in FABP5 inhibition, aligning with previous cancer research. Despite a signifi", "url": "https://m.uk.investing.com/news/stock-market-news/artelo-presents-research-on-fabp5-inhibitor-art2612-93CH-4750728?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-01T08:40:08", "published_display": "01 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026", "summary": "Artelo Biosciences announced multi-omics analysis results at the ICRS 2026 Annual Symposium, highlighting linoleic acid as a critical lipid modulated by their lead FABP5 inhibitor, ART26.12. This finding suggests a common mechanistic link for FABP5 inhibition across various disea", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/artelo-biosciences-presents-evidence-for-a-common-lipid-signaling-link-across-multiple-potential-indications-for-its-fabp5-inhibitor-platform-at-icrs-2026/2375833/amp", "source_name": "The Manila Times", "published_at": "2026-06-30T21:09:06", "published_display": "30 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo says its FABP5 inhibitor hits a key lipid pathway across disease models", "summary": "Artelo Biosciences announced new multi-omics data for its selective FABP5 inhibitor, ART26.12, showing consistent modulation of the pro-inflammatory lipid linoleic acid and related lipid-signaling pathways across various disease models. This suggests a potential mechanistic link ", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-presents-evidence-for-a-common-lipid-signaling-kg1z5lyxzgae.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:39:30", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research", "summary": "Artelo Biosciences announced positive Phase 1 clinical trial results for ART26.12, its selective FABP5 inhibitor, showing a favorable safety profile and predictable pharmacokinetics. The study highlighted ART26.12's potential as a non-opioid analgesic for chemotherapy-induced per", "url": "https://www.quiverquant.com/news/Artelo+Biosciences+Reports+Positive+First-in-Human+ART26.12+Safety+and+Pharmacokinetic+Results%2C+Advances+AI-Enabled+Biomarker+Research", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T21:09:06", "published_display": "29 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo\u2019s first-in-human FABP5 inhibitor shows tolerability, biomarker signals", "summary": "Artelo Biosciences reported positive Phase 1 clinical data for its selective FABP5 inhibitor, ART26.12, at ICRS 2026. The study found ART26.12 to be well-tolerated with predictable pharmacokinetics, and AI-driven analysis identified treatment-related changes in various biological", "url": "https://www.stocktitan.net/news/ARTL/artelo-biosciences-presents-clinical-and-biomarker-data-supportive-pjjo1myuhfej.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:10:13", "published_display": "29 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026", "summary": "Artelo Biosciences announced the presentation of clinical and biomarker data for ART26.12, its selective FABP5 inhibitor, at the ICRS 2026 Annual Symposium. The presentations highlighted favorable safety and pharmacokinetic profiles from a Phase 1 study and identified potential b", "url": "https://sg.finance.yahoo.com/news/artelo-biosciences-presents-clinical-biomarker-124500525.html", "source_name": "Market source", "published_at": "2026-06-29T13:10:13", "published_display": "29 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Inc Actuals & Estimates (NASDAQ:ARTL)", "summary": "This article provides details on Artelo Biosciences, Inc. (NASDAQ: ARTL), including its current stock price, historical performance, market capitalization, and upcoming earnings report. As of June 26, 2026, ARTL's stock price is $1.12, having decreased significantly year-over-yea", "url": "https://www.tradingview.com/symbols/NASDAQ-ARTL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:21", "published_display": "26 Jun 2026 19:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) asks shareholders to approve >20% issuance to Square Gate", "summary": "Artelo Biosciences is seeking shareholder approval for Proposal 3, which would allow the company to issue more than 20% of its common stock under an existing Equity Purchase Agreement (EPA) with Square Gate Capital Master Fund, LLC \u2013 Series 5. This approval is necessary to comply", "url": "https://www.stocktitan.net/sec-filings/ARTL/prer14a-artelo-biosciences-inc-preliminary-revised-proxy-statement-0ac81b42277c.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:14", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides an analysis of Artelo Biosciences Inc (ARTL), detailing its stock performance and market capitalization. It highlights that critical revenue breakdown data, including information by business segment and region, has not yet been disclosed by the company. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-artl/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:15:28", "published_display": "18 Jun 2026 09:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/artelo-biosciences-presents-art26-12-113800180.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:38:00+00:00", "published_display": "10 Jun 2026 11:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTL Stock In Focus As Artelo Biosciences Taps AI For Drug Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOVTNiNFZSc1Z2ZGRsakhSeUVva1lzczJyajJWMEpIMlNvdTBsTGI0MVJ1WTRURWY1MENHakVQRU51Q08xcVFHSFdRR2tFLXVybGRPVmhObW10WC1qMU9xWWd5STh5VDdFeDcwM3hKN3JLclRCdGxUaHVGZjhhMF8zVg?oc=5", "source_name": "StocksToTrade", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo keeps Nasdaq listing after fixing equity, meeting gaps", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQckFoNERSUmhWLU01aUFrNGZWdjBxSVhQTE95LUJJemxFUXJXcE1GZFMxQ09tcjBVZjBXM0x3U3BNU2NZM2xUX3JDRmJ1cnhNNm15UXY5NWduY3Z6SWFXTzFlZU1zYjQ3cEFFSWU2QzJDWlBId1p6TG9XUFNqMnRCN3hGQjdQcnZzRXhKWmxpM08zejdNcjB4YVVYZ3BvV01KVHh3T05uVk96UWM3RTlmTEx3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] ARTELO BIOSCIENCES, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNY0hrLW8yOHQzQ1htTDYxT012VlczamFtcjdnZDBUX1VTR0xUMFh6REViSlFINzBxWU1lTW5tZU56ZnhlSklua1JMSlF3ZVgwZkgxRmhNdm9DWHZPQmxqWEJ6YUpBMGN3clpUbVh5NDhYSjdSREVmN0N6cU1Dc1B3Q2hsQ2VaUWFaakNJQ1RvZWc3TzFBYlY5b3lyd1dVTFAzZ2VkZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo raises $11M now; warrant exercise would add $20.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMHN5VEQ0dW1ydENmVjlNcDUtZVpvTWtWalNlYXpmTExROEV4bzVmX2dLbHVXdzRsUWlKd2toMTFscFBkQWZsY0JGcmdBYTN5ejN6TjIxQmRaOHhOYzhXaVFsS0laRkVETGlhOFFoR1J6bFJ5X0JOTVl5X0JBVWQ1SGxFOWhuV1J0Zmk0Z3R0SkRiRnR6M1dOekpTVmdlbFdLRTBQbHBBbEdRdElURzRsNElqZzhmZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences, Inc. Completes $11 Million Private Placement of Common Stock and Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNb2lOSGpSeDVyeEU2RXJCcHZxenM1YS1kS2RFSTBGeGx4aU9OUzhtalp4VzVIR2xJWGhiUld3eHAwUk03WnlET2FyZnJnS25tNzBXY1liZ005TlhvQzI5eGd6VW8xbkItRjVnc2hOS3drakFuWkp0eC01YnFZeGVYd3dHU19fVmh3bGI2VmJ4SXVtZl9FZFY5dElvdERDbktkR254Szc2Ti1mSEplcUhoVjZmSzMzZ1F1OTRZdW11c2xRUFlpYUFjVXJ3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxOQ01pOUQ0SzU1SWFLWjZDTHZMNFF0V3BMcEdiQXNmLVduNjRrSG1RM3gwUEpJcGhnbHpyQVAwVTVQcUJ6X3hsLUlhNjFUMnJwNW5GMVgwOEFfekNUZ082bEI1bzBONEFVVHUzSlRGRC1aU3ZCd0NsZ2VwQnFUTEJFQnEwMXkza0otSE1EbXpDM0FEYUVhZ1hFUkg0bFdhZEhfVlF5MElZZVVTcnozRnotZUlmZmtZejJUTXFZa3J5a2dEZWxZcXAyMTJ5OEwtQm5CbHhXTWl6MkxqaU1fVEQ0V2d5VHBpbHFfZ0pKdzRROVpqS24tR182Z2IzTlFMNXdoVjM1VHFROEUxLWVTN3pz?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences, Inc. Announces Private Placement of Common Stock and Warrants, Expected Proceeds of $11 Million | ARTL Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPZUZKSTAyam1VbkFROUVXTTBRU0U0dVdncmxPdHNiVzJYWDRhZVB2aUVtNEdGSUg2NTZ6OC1VWUdiT1BzVWcwbE5OTU9TSWlFR2JVcWpETm4yRDNXNjZNTzg4YmIzUWlLd0k2d1Vhck42N3ZFNVhzX1FPVXUtZFhuZm5WV1BqQ3pVQm51LTE2UkxCWkV6ZFJCMjA4bU5tZGxUU1NsaVJQRElTWU5ZVDdGcUx2clczdXAzWUhCRmhSRWxjeVZNUlk3bEE1VWF0eVF3eDlpS0tfbTdnNm1UMEV0dm90YkUxWl9RZ0E?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPRlUwQm9KNHY4U3VxeUZpZ0YwZHB2ZVEtMWN4WnE1S0JKRVI4TDd5UTJLbEVYdFhKUVhtUVNCM3kwN2NEOXJET1lUY3FpeDdJU0xjSzJqTkViY1p4cTYwMU1ldnNRUWZnbFRQSm5UekNqRU1FWVpXb203V0prMzFsOXRzUmZ2ckNtaDhqUnV6NnBKbDIxeHJZT2hRSXNoTmgydkJqb2VHMEs1Y2dvN3NnNk5BMjlUOWgyMWJZTjJkekdKUFFxZ05VWnRMcHdSczRRYTBqcWFsa1liSUtmOHdJREpvVW1mb2FnTk5EZzRPRkt5c3dUUG5zdlNpQ0ZHcVpL?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$11M Artelo stock sale targets debt repayment, working capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQdkxrejE1SDgxYUNkTFJWb1NzZnBOblhLZ3oxcjlLU0xfNlZ0Z3dHR1JjaWd4YzJYZ21PMldJRjNwck5GZmtMcGIycDdQMldVb0YydWxfem02RnpkWFl4b1ZRSFNnRE9jX0NNc1RKS2QyWTNKclNJdFpHLW1DSlZYNWZVT1l1YU5kTFc4blpzLUpXZDEwX0xDcy11dlhrQmkyS18tVVVrV0tybFRyQU5TYUpyUUV6M3VBTk52bUhR?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARTELO BIOSCIENCES, INC. SEC Filing (Mar 27, 2026) | ARTL RW", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNVEZlSWw5U0JVTUtjMmp4UzVhYk5NWlhfMWk1cExzOXp4aU01SlF0YjcwY19sdkdsNEpaUHFMOFJmb2s2SHZWVjg4T21FVWlvZmRWbXpCQ1FsUmQzM3o4c3hmVzdLdDZDNjJVYi1tN0JkUk9jSmV0ckxsUWVXMDRvUFBhd0Y1RGpmTE9pa3U1MFRZdy1VaTlQaThPbnF1N0k?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo takes its lead drug into glaucoma without paying for the trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdGxyejNaYTRjSE93YnI1Z25uYmdTalQ4clhkM1ZBQmdYVkp2QUdrOW5uMUdLZTlkWUhTXzNWYzBvQmI4QkhGNFpDZUJXcEZVQ3dhdmdtRWRva181SHFHNFVxVUNHMEJBXy1kNGN3bTljeC1nTExNdndVTlpuVEVDMTZPb2RLVFBYekFYUWZhVXZwZkd6ckVjb01mQjBaalZoVDBodHlTVGJmS19WREktMTRwY2kyeE1tY0tTYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo shrinks share count to 708K in 3-for-1 reverse split", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQUU9UYzhNM3lJSV9wQVNBWWNRaExHRHhDdlBGX3RWRlg0bjdaSVllVHR6c0V4NjZYRTRHM3RhYUpNY3BCRVMxYm53RDN6N09raXFsdHdUbzZ4TmtJUGZDR01QZFUxN2RYODRQb1FPNXVrMEVyNGpfc0hFQS1LampWSEN1ME04T3NSRXB3UHhXMWdEM3JJa0taY0VfOWtBQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artelo Biosciences (ARTL) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5wX25RY0toY3FBVmNuWUtxd1paUnhPY19VU2lsYVZvcGcxUnBaZFhkVU4zYXU5R2dXczM4aG5Zd0dodldqRW1lanFVTWZVYWc5NHpB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:14:23+00:00", "published_display": "25 Apr 2025 02:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 59, "sentiment_summary": {"positive": 20, "negative": 3, "neutral": 36, "score": 58, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 19.8, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 9.76, "count": 20}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.15, "latest_week": "2026-07-17", "one_week_move": 6.5, "four_week_move": -8.7, "twelve_week_move": -71.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.782445, "market_dynamics_buy_signal": false, "relative_strength": -88.79229, "fair_value_gap": -93.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.8783, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.5% over one week, -8.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 20}, {"label": "Market source", "count": 9}, {"label": "Quiver Quantitative", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "The Manila Times", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Quartr", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 20}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.5% over one week, -8.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney"}], "updated_at": "2026-07-22T03:47:01.391816+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}